Daicel (JP:4202)
:4202
Top Page
Daicel
(4202)
Select Model
Select Model
Rating:80Outperform
Price Target:
¥1,740.00
▲(30.58% Upside)
Action:ReiteratedDate:10/30/25
Daicel's strong financial performance and attractive valuation are the primary drivers of its overall score. While technical indicators suggest some short-term bearishness, the stock's low P/E ratio and high dividend yield provide significant upside potential. The absence of earnings call data and corporate events does not impact the score.
Positive Factors
Revenue & Margin Stability
Daicel's steady revenue expansion to ¥586.5bn and consistently strong gross margins above 27% indicate durable demand for its specialty chemistries and safety components. Stable margins provide a structural buffer against input swings, supporting reinvestment, R&D and predictable cash generation over the medium term.
Negative Factors
High Total Debt
Total debt of ¥280.9bn represents a material liability that raises interest and refinancing exposure. Over a multi-month horizon, sustained high leverage can constrain capital allocation, limit M&A or R&D spending flexibility, and heighten vulnerability to rising rates or cyclical revenue downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Stability
Daicel's steady revenue expansion to ¥586.5bn and consistently strong gross margins above 27% indicate durable demand for its specialty chemistries and safety components. Stable margins provide a structural buffer against input swings, supporting reinvestment, R&D and predictable cash generation over the medium term.
Read all positive factors
Daicel (4202) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥347.42B
Dividend Yield4.27%
Average Volume (3M)536.76K
Price to Earnings (P/E)5.5
Beta (1Y)1.06
Revenue Growth-0.48%
EPS Growth-35.29%
CountryJP
Employees11,134
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)64.09
Shares Outstanding266,942,700
10 Day Avg. Volume480,400
30 Day Avg. Volume536,760
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)0.98
Price to Sales (P/S)0.60
P/FCF Ratio15.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,479.36Price Target Upside11.02% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)194.12
Revenue Forecast (FY)¥576.40B
Daicel Business Overview & Revenue Model
Company Description
Daicel Corporation manufactures and sells cellulosic derivatives, organic chemicals, plastics, pyrotechnic devices, and other products in Japan, Asia, North America, and Europe. It operates through Medical/Healthcare, Smart, Safety, Materials, Eng...
How the Company Makes Money
Daicel generates revenue through several key streams, primarily from the manufacturing and sale of its chemical products and materials. The company has a strong presence in the automotive sector, providing essential components such as airbags and ...
Daicel Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 578.81B | 586.53B | 558.06B | 538.03B | 467.94B | 393.57B |
| Gross Profit | 153.46B | 165.84B | 160.39B | 147.04B | 139.68B | 113.49B |
| EBITDA | 92.89B | 102.38B | 96.10B | 79.08B | 78.89B | 59.13B |
| Net Income | 41.14B | 49.48B | 55.84B | 40.68B | 31.25B | 19.71B |
Balance Sheet | ||||||
| Total Assets | 884.09B | 813.83B | 839.17B | 765.61B | 698.84B | 640.38B |
| Cash, Cash Equivalents and Short-Term Investments | 75.85B | 65.14B | 73.18B | 93.84B | 90.53B | 91.54B |
| Total Debt | 317.90B | 286.12B | 304.12B | 321.97B | 283.55B | 270.94B |
| Total Liabilities | 483.88B | 438.79B | 464.30B | 455.17B | 419.29B | 395.38B |
| Stockholders Equity | 384.69B | 359.99B | 358.90B | 295.21B | 272.02B | 237.85B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 23.44B | 11.11B | -20.54B | -501.00M | 23.17B |
| Operating Cash Flow | 0.00 | 93.41B | 76.73B | 26.85B | 42.99B | 57.87B |
| Investing Cash Flow | 0.00 | -47.87B | -55.37B | -36.89B | -46.53B | -34.22B |
| Financing Cash Flow | 0.00 | -48.85B | -52.37B | 12.76B | -5.45B | -17.05B |
Daicel Technical Analysis
Negative
1332.50
Price Trends
1503.22
Negative
1420.54
Negative
1353.89
Negative
Market Momentum
-56.06
Positive
33.28
Neutral
14.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4202, the sentiment is Negative. The current price of 1332.5 is below the 20-day moving average (MA) of 1455.15, below the 50-day MA of 1503.22, and below the 200-day MA of 1353.89, indicating a bearish trend. The MACD of -56.06 indicates Positive momentum. The RSI at 33.28 is Neutral, neither overbought nor oversold. The STOCH value of 14.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4202.
Daicel Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥347.42B | 5.46 | 9.34% | 4.27% | -0.48% | -35.29% | |
79 Outperform | ¥337.72B | 14.16 | 9.59% | 3.91% | 0.87% | 16.71% | |
76 Outperform | ¥404.07B | 17.67 | 6.52% | 1.82% | 3.25% | -11.31% | |
74 Outperform | ¥298.55B | 9.05 | 5.47% | 3.41% | 2.60% | 9.50% | |
67 Neutral | ¥746.10B | 77.75 | -2.50% | 3.49% | -6.83% | -123.67% | |
65 Neutral | ¥236.71B | 6.13 | 1.47% | 4.29% | -7.45% | -71.68% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
* Basic Materials Sector Average
JP:4202
Daicel
1,358.00
30.26
2.28%
JP:4118
Kaneka
4,785.00
910.65
23.50%
JP:4182
Mitsubishi Gas Chemical Company
4,045.00
1,672.24
70.48%
JP:4208
UBE Industries
2,514.00
316.07
14.38%
JP:4205
Zeon
1,844.00
323.57
21.28%
JP:4203
Sumitomo Bakelite Co., Ltd.
5,090.00
1,595.05
45.64%
Daicel Corporate Events
Daicel Advances Share Buyback, Repurchasing Over 8.5 Million Shares
Mar 3, 2026
Daicel has continued its share repurchase program, acquiring 700,200 shares of its common stock for about ¥1.14 billion on the Tokyo Stock Exchange between February 1 and February 28, 2026. This move is part of a previously approved buyback f...
Daicel Delays New COC Resin Plant as EU Packaging Shift Slows Demand
Feb 5, 2026
Daicel has revised its business plan for its cyclic olefin copolymer (COC) business and decided to postpone the start of operations at a new COC resin plant in Germany, following slower-than-expected demand growth and sharply higher construction a...
Daicel Earnings Decline on Weaker Profitability but Full-Year Outlook and Dividend Remain Intact
Feb 5, 2026
Daicel reported consolidated net sales of ¥424.8 billion for the nine months ended December 31, 2025, down 1.8% year-on-year, with operating profit falling 25.0% to ¥32.4 billion and profit attributable to owners of parent declining 18.9...
Daicel Advances Share Buyback, Repurchasing 7.8 Million Shares Under Ongoing Program
Feb 3, 2026
Daicel Corporation has been actively repurchasing its own shares as part of a board-approved share buyback program, reflecting a capital allocation strategy aimed at enhancing shareholder value and optimizing its capital structure. In January 2026...
Daicel to Absorb Polyplastics’ Operating Business and Rename Subsidiary HPP Holdings
Jan 15, 2026
Daicel Corporation will integrate all operating businesses of its wholly owned subsidiary Polyplastics Co., Ltd. into the parent company via a simplified absorption-type company split effective April 1, 2026, while excluding Polyplastics’ sh...
Daicel Advances Share Buyback, Repurchasing Over 6 Million Shares by Year-End 2025
Jan 6, 2026
Daicel Corporation has reported progress on its ongoing share buyback program, acquiring 1,878,500 shares of its common stock for approximately ¥2.53 billion on the Tokyo Stock Exchange between December 1 and December 31, 2025. This forms par...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.